US 12,173,327 B2
Platforms and systems for automated cell culture
Matthias Wagner, Cambridge, MA (US); Suvi Aivio, Arlington, MA (US); Mariangela Amenduni, Arlington, MA (US); Catherine Pilsmaker, Arlington, MA (US); Arnaldo Pereira, Cambridge, MA (US); Ananya Zutshi, Boston, MA (US); Anthia Toure, Boston, MA (US); Steven Nagle, Wayland, MA (US); Ozge Whiting, Pawtucket, RI (US); George Harb, Providence, RI (US); Matthew Sullivan, Westwood, MA (US); Maya Berlin-Udi, Acton, MA (US); Stefanie Morgan, Hanover, MA (US); Nick Seay, Charlottesville, VA (US); Sang Lee, Newton, MA (US); and Scott Luro, Somerville, MA (US)
Assigned to Cellino Biotech, Inc., Cambridge, MA (US)
Filed by Cellino Biotech, Inc., Cambridge, MA (US)
Filed on Jun. 22, 2023, as Appl. No. 18/339,779.
Application 18/339,779 is a continuation of application No. 18/190,775, filed on Mar. 27, 2023.
Application 18/190,775 is a continuation of application No. 17/688,859, filed on Mar. 7, 2022, granted, now 11,680,247, issued on Jun. 20, 2023.
Claims priority of provisional application 63/311,673, filed on Feb. 18, 2022.
Claims priority of provisional application 63/298,241, filed on Jan. 11, 2022.
Claims priority of provisional application 63/297,290, filed on Jan. 7, 2022.
Claims priority of provisional application 63/295,968, filed on Jan. 3, 2022.
Claims priority of provisional application 63/288,859, filed on Dec. 13, 2021.
Claims priority of provisional application 63/284,839, filed on Dec. 1, 2021.
Claims priority of provisional application 63/282,351, filed on Nov. 23, 2021.
Claims priority of provisional application 63/249,698, filed on Sep. 29, 2021.
Claims priority of provisional application 63/239,995, filed on Sep. 2, 2021.
Claims priority of provisional application 63/226,128, filed on Jul. 27, 2021.
Claims priority of provisional application 63/222,059, filed on Jul. 15, 2021.
Claims priority of provisional application 63/216,558, filed on Jun. 30, 2021.
Claims priority of provisional application 63/210,243, filed on Jun. 14, 2021.
Claims priority of provisional application 63/196,904, filed on Jun. 4, 2021.
Claims priority of provisional application 63/194,306, filed on May 28, 2021.
Claims priority of provisional application 63/167,114, filed on Mar. 28, 2021.
Claims priority of provisional application 63/157,731, filed on Mar. 7, 2021.
Prior Publication US 2023/0332111 A1, Oct. 19, 2023
Int. Cl. G06K 9/00 (2022.01); B01L 3/00 (2006.01); B01L 9/00 (2006.01); C12M 1/00 (2006.01); C12M 1/06 (2006.01); C12M 1/12 (2006.01); C12M 1/26 (2006.01); C12M 1/34 (2006.01); C12M 1/36 (2006.01); C12M 3/00 (2006.01); C12N 5/00 (2006.01); C12N 5/074 (2010.01); G01N 15/10 (2006.01); G01N 15/1429 (2024.01); G01N 15/1433 (2024.01); G01N 15/1434 (2024.01); G06T 7/00 (2017.01); G01N 15/14 (2006.01)
CPC C12N 5/0696 (2013.01) [B01L 3/502715 (2013.01); B01L 3/502761 (2013.01); B01L 9/52 (2013.01); C12M 23/14 (2013.01); C12M 23/22 (2013.01); C12M 23/26 (2013.01); C12M 23/28 (2013.01); C12M 23/42 (2013.01); C12M 23/44 (2013.01); C12M 23/48 (2013.01); C12M 25/06 (2013.01); C12M 27/02 (2013.01); C12M 29/02 (2013.01); C12M 31/02 (2013.01); C12M 33/00 (2013.01); C12M 33/12 (2013.01); C12M 41/12 (2013.01); C12M 41/26 (2013.01); C12M 41/44 (2013.01); C12M 41/46 (2013.01); C12M 41/48 (2013.01); C12M 47/04 (2013.01); C12N 5/0081 (2013.01); G01N 15/1023 (2024.01); G01N 15/1429 (2013.01); G01N 15/1433 (2024.01); G01N 15/1434 (2013.01); G06T 7/0012 (2013.01); G06T 7/0016 (2013.01); B01L 2200/18 (2013.01); B01L 2300/0663 (2013.01); B01L 2300/0877 (2013.01); C12M 41/36 (2013.01); G01N 2015/1006 (2013.01); G01N 2015/1452 (2013.01); G01N 2015/1454 (2013.01); G01N 2015/1486 (2013.01); G06T 2207/10056 (2013.01); G06T 2207/10064 (2013.01); G06T 2207/20081 (2013.01); G06T 2207/30024 (2013.01); G06T 2207/30072 (2013.01)] 30 Claims
OG exemplary drawing
 
1. A method of manufacturing induced pluripotent stem cells (iPSCs) for a plurality of subjects in parallel, the method comprising:
(a) for each subject in the plurality of subjects, associating the subject with a closed bioprocessing module of a plurality of closed bioprocessing modules, wherein each closed bioprocessing module of the plurality of closed bioprocessing modules comprises one or more sealed cell culture chambers fluidically coupled to a sterile closed loop liquid system;
(b) culturing, for each of the plurality of subjects, iPSCs obtained or derived from the subject in the associated closed bioprocessing module of the plurality of closed bioprocessing modules for the subject, wherein the iPSCs are adhered to an at least partially transparent surface of each of the one or more sealed cell culture chambers in the associated closed bioprocessing module;
(c) expanding, for each of the plurality of subjects in parallel, the iPSCs cultured in the associated closed bioprocessing module, wherein expanding the iPSCs comprises:
(i) collecting, by an imaging system shared by the plurality of closed bioprocessing modules associated with each of the plurality of subjects, time-series images of the one or more sealed cell culture chambers in each of the plurality of closed bioprocessing modules associated with the plurality of subjects;
(ii) selecting, by a computing system shared by the plurality of closed bioprocessing modules associated with each of the plurality of subjects, one or more cells to remove from the one or more sealed cell culture chambers in each of the plurality of closed bioprocessing modules associated with the plurality of subjects; and
(iii) removing, by a cell editing system shared by the plurality of closed bioprocessing modules associated with each of the plurality of subjects, the selected one or more cells from the one or more sealed cell culture chambers in each of the plurality of closed bioprocessing modules associated with the plurality of subjects; and
(d) harvesting, for each of the plurality of subjects, an iPSC output product from the plurality of closed bioprocessing modules associated with the plurality of subjects.